本文選題：坦洛新 + 托特羅定�。� 參考：《青海大學(xué)》2014年碩士論文

【摘要】：目的：研究坦洛新（tamsulosion）與托特羅定（tolterodine）治療前列腺增生合并逼尿肌不穩(wěn)定(benign prostatic hyperplasia,BPH)，坦洛新與托特羅定單獨用藥對比兩種藥物聯(lián)合用藥在前列腺增生合并逼尿肌不穩(wěn)定的治療與預(yù)后的效果分析。方法：收集前列腺增生合并逼尿肌不穩(wěn)定患者91例作為研究對象，（依據(jù)坦洛新和托特羅定聯(lián)合用藥與單獨用藥）將其分為3組，在3組中進行比較。每組研究對象就診前分別測定前列腺癥狀國際評分（I-PSS）、膀胱過度活動癥評分（OABSS）、膀胱殘尿量(RUV)、最大尿流率（QMAX）。實驗組每日口服坦洛新膠囊，0.2mg/次，每日1次，每日口服托特羅定片，2mg/次，每日2次。治療12周后再次復(fù)查上述四項指標。對照組A每日口服坦洛新膠囊，0.2mg/次，每日1次，治療12周后再次復(fù)查上述四項指標。對照組B每日口服托特羅定片，2mg/次，每日2次，治療12周后復(fù)查上述四項指標。結(jié)果：實驗組患者治療12周后I-PSS評分、OABSS評分、RUV、QMAX分別為（11.3±2.0）,(1.7±0.4),(19.6±4.1),(16.3±3.9)。對照組A患者治療12周后I-PSS評分、OABSS評分、RUV、QMAX分別為（16.2±2.1）,(3.6±0.6),(19.1±3.7),(15.1±2.1)。對照組B患者治療12周后I-PSS評分、OABSS評分、RUV、QMAX分別為（17.2±2.1）,(3.6±0.7),(35.7±3.9),(11.1±3.1)。實驗組患者治療后上述前列腺相關(guān)指標明顯改善，其數(shù)據(jù)與對照組比較有統(tǒng)計學(xué)差異（P0.05）。結(jié)論：坦洛新聯(lián)合托特羅定治療前列腺增生合并逼尿肌不穩(wěn)定效果顯著，可明顯改善患者儲尿期下尿路癥狀及患者生活質(zhì)量。托特羅定適當劑量用藥不會影響逼尿肌排尿功能。
[Abstract]:Objective: to study the effects of Thaloxine and tolterodine in the treatment of prostatic hyperplasia with detrusor instability, tenlosin and tolterodine alone in the treatment of prostatic hyperplasia with detrusor instability. Effect analysis of treatment and prognosis. Methods: 91 patients with benign prostatic hyperplasia complicated with detrusor instability were divided into 3 groups. The international score of prostatic symptoms (I-PSSN), bladder hyperactivity score (OABSS), bladder residual urine volume (RUVN), and maximal urinary flow rate (MVF) were measured before treatment. The experimental group was treated with Thaloxin capsule 0.2 mg / d once a day and Totterodine 2 mg / d twice a day. After 12 weeks of treatment, the above four indexes were reviewed again. The control group A was treated with 0.2 mg / d Tanluoxin capsule once a day. After 12 weeks of treatment, the above four indexes were reviewed again. Control group B was treated with toterodine 2mg / d, twice a day. After 12 weeks of treatment, the above four indexes were reviewed. Results: after 12 weeks of treatment, the I-PSS scores and the RUV QMAX of the patients in the experimental group were 11.3 鹵2.0 and 1.7 鹵0.4, respectively, and were 19.6 鹵4.1 and 16.3 鹵3.9 respectively. In the control group, the I-PSS score and the I-PSS score were 16.2 鹵2.1 and 3.6 鹵0.6 respectively after 12 weeks of treatment, and the I-PSS scores were 19.1 鹵3.7 and 15.1 鹵2.1 respectively. In the control group, the I-PSS score and the I-PSS score were 17.2 鹵2.1, 3.6 鹵0.7, 35.7 鹵3.9 and 11.1 鹵3.1 respectively after 12 weeks of treatment in the control group. Compared with the control group, the patients in the experimental group improved the above prostatic index significantly, and the data were significantly different from that of the control group (P 0.05). Conclusion: Thaloxin combined with tolterodine is effective in the treatment of benign prostatic hyperplasia with detrusor instability, and can improve the symptoms of the lower urinary tract and the quality of life of the patients. Proper dosage of tolterodine does not affect detrusor urination function.
【學(xué)位授予單位】：青海大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R697.3

【參考文獻】

相關(guān)期刊論文 前2條

1 葉章群;;良性前列腺增生的診斷和治療[J];中華老年醫(yī)學(xué)雜志;2006年05期

2 吳喜英;何可可;李磊;;良性前列腺增生癥3種藥物治療方案的成本-效果分析[J];中國現(xiàn)代藥物應(yīng)用;2008年02期

，

本文編號：1921301